In this case, instead of selecting the treatment based on the most likely, but not necessarily definitive, diagnosis, given the tumor’s known PIK3CA gain-of-function effect, alpelisib was considered and ultimately found to be extremely successful even with imperfect use by the patient. The gene discussed is PIK3CA; the disease is neoplasm.